Original Research

Published on 28 Jun 2024

Sugemalimab combined with chemotherapy for the treatment of advanced esophageal squamous cell carcinoma: a cost-effectiveness analysis

in Pharmacology of Anti-Cancer Drugs

Hongfu Cai
Ling Fang
Zhiwei Zheng

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1396761

774 views

Original Research

Published on 28 Jun 2024

B4 suppresses lymphoma progression by inhibiting fibroblast growth factor binding protein 1 through intrinsic apoptosis

in Pharmacology of Anti-Cancer Drugs

Krishnapriya M. Varier
Gou Dan
Xiaolong Li
Wuling Liu
Fei Jiang
Ke-Gang Linghu
Yanmei Li
Yaacov Ben-David
Nenling Zhang
Chaoda Xiao

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1408389

1,180 views

Opinion

Published on 27 Jun 2024

Repurposing therapy of ibrexafungerp vulvovaginal candidiasis drugs as cancer therapeutics

in Pharmacology of Anti-Cancer Drugs

Tedi Rustandi
Abdul Mahmud Yumassik
Fitrah Shafran Ilahi
Riza Alfian
Erna Prihandiwati
Yugo Susanto
Yudi Hardi Susilo
Maria Ulfah
Faizatun Faizatun

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1428755

1,019 views

Review

Published on 27 Jun 2024

Lipid metabolism dynamics in cancer stem cells: potential targets for cancers

in Pharmacology of Anti-Cancer Drugs

Juan Du
Hai Qin

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1367981

1,220 views

Systematic Review

Published on 26 Jun 2024

Adverse renal outcomes following targeted therapies in renal cell carcinoma: a systematic review and meta-analysis

in Pharmacology of Anti-Cancer Drugs

Song Ren
Xiuling Chen
Yang Zheng
Tingwei Chen
Xu Hu
Yunlin Feng
Shangqing Ren

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1409022

852 views

Mini Review

Published on 26 Jun 2024

Metabolic reprogramming in esophageal squamous cell carcinoma

in Pharmacology of Anti-Cancer Drugs

Ziyi Wang
Xiangyu Sun
Zehui Li
Huidong Yu
Wenya Li
Yan Xu

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1423629

1,185 views

Original Research

Published on 26 Jun 2024

Mechanism of baicalein in treatment of castration-resistant prostate cancer based on network pharmacology and cell experiments

in Pharmacology of Anti-Cancer Drugs

Baokai Dou
Yingjie Cui
Qianqian Zhou
Jiawei Fu
Yi Zhou
Xiwu Zhang
Qi Zhang
Jing Zhang

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1397703

1,384 views
1 citation

Original Research

Published on 25 Jun 2024

Prediction of immunotherapy response of bladder cancer with a pyroptosis-related signature indicating tumor immune microenvironment

in Pharmacology of Anti-Cancer Drugs

Zihan Xu
Yujie Zhao
Yong Zhang
Xiaowei Liu
Linlin Song
Meixu Chen
Guixiu Xiao
Xuelei Ma
Hubing Shi

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1387647

1,166 views
1 citation

Original Research

Published on 25 Jun 2024

A real-world pharmacovigilance study of polatuzumab vedotin based on the FDA adverse event reporting system (FAERS)

in Pharmacology of Anti-Cancer Drugs

Dan Liu
Wei Mao
Bin Hu
Xingxing Li
Quanfeng Zhao
Lin Zhang
Jing Hu

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1405023

1,944 views
1 citation

Original Research

Published on 25 Jun 2024

NDRG1 acts as an oncogene in triple-negative breast cancer and its loss sensitizes cells to mitochondrial iron chelation

in Pharmacology of Anti-Cancer Drugs

Sukanya B. Jadhav
Michaela Vondrackova
Petra Potomova
Cristian Sandoval-Acuña
Jana Smigova
Kristyna Klanicova
Daniel Rosel
Jan Brabek
Jan Stursa
Lukas Werner

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1422369

1,374 views
1 citation

Mini Review

Published on 25 Jun 2024

The role of lactate-induced protein lactylation in gliomas: implications for preclinical research and the development of new treatments

in Pharmacology of Anti-Cancer Drugs

Xiaoying Liu
Yue Zhou
Haichuan Wang

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1383274

1,786 views

Case Report

Published on 21 Jun 2024

Case report: successful response to bevacizumab combined with erlotinib for a novel FH gene mutation hereditary leiomyoma and renal cell carcinoma

in Pharmacology of Anti-Cancer Drugs

Xiaoming Bai
Dan Xiang
Mengxi Huang
Yitian Chen

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1373020

1,221 views
1 citation

Systematic Review

Published on 21 Jun 2024

Assessing the benefits and safety profile of incorporating poly ADP-ribose polymerase (PARP) inhibitors in the treatment of advanced lung cancer: a thorough systematic review and meta-analysis

in Pharmacology of Anti-Cancer Drugs

Min Tang
Yue Wang
Pulin Li
Rui Han
Ran Wang

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1338442

810 views

Systematic Review

Published on 21 Jun 2024

Effectiveness and safety of brucea javanica oil assisted TACE versus TACE in the treatment of liver cancer: a systematic review and meta-analysis of randomized controlled trials

in Pharmacology of Anti-Cancer Drugs

Zhi-Hai Wu
Hai-Feng Zhang
Jun-Yan Li
Yi-Rui Diao
Man-Jing Huang
Dong-Yang Gao
Chang-Hao Liang
Zhi-Qiang Luo

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1337179

770 views
1 citation

Mini Review

Published on 20 Jun 2024

Exploiting gender-based biomarkers and drug targets: advancing personalized therapeutic strategies in hepatocellular carcinoma

in Pharmacology of Anti-Cancer Drugs

Lanqian Su
Huanyu Luo
Yalan Yan
Zhongqiu Yang
Jiaan Lu
Danqi Xu
Linjuan Du
Jie Liu
Guanhu Yang
Hao Chi

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1433540

1,032 views
2 citations

Case Report

Published on 20 Jun 2024

Case report: a cataract induced by bleomycin in a patient with testicular cancer

in Pharmacology of Anti-Cancer Drugs

Wan Zhang
Yinghua Ji
Yufei Sun
Keya Zhi
Han Yang
Min Zhang
Ping Lu
Yana Zhang

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1339662

742 views
2 citations

Navigation group

Articles

Sugemalimab combined with chemotherapy for the treatment of advanced esophageal squamous cell carcinoma: a cost-effectiveness analysis

B4 suppresses lymphoma progression by inhibiting fibroblast growth factor binding protein 1 through intrinsic apoptosis

Repurposing therapy of ibrexafungerp vulvovaginal candidiasis drugs as cancer therapeutics

Lipid metabolism dynamics in cancer stem cells: potential targets for cancers

Adverse renal outcomes following targeted therapies in renal cell carcinoma: a systematic review and meta-analysis

Metabolic reprogramming in esophageal squamous cell carcinoma

Mechanism of baicalein in treatment of castration-resistant prostate cancer based on network pharmacology and cell experiments

Prediction of immunotherapy response of bladder cancer with a pyroptosis-related signature indicating tumor immune microenvironment

A real-world pharmacovigilance study of polatuzumab vedotin based on the FDA adverse event reporting system (FAERS)

NDRG1 acts as an oncogene in triple-negative breast cancer and its loss sensitizes cells to mitochondrial iron chelation

The role of lactate-induced protein lactylation in gliomas: implications for preclinical research and the development of new treatments

Case report: successful response to bevacizumab combined with erlotinib for a novel FH gene mutation hereditary leiomyoma and renal cell carcinoma

Assessing the benefits and safety profile of incorporating poly ADP-ribose polymerase (PARP) inhibitors in the treatment of advanced lung cancer: a thorough systematic review and meta-analysis

Effectiveness and safety of brucea javanica oil assisted TACE versus TACE in the treatment of liver cancer: a systematic review and meta-analysis of randomized controlled trials

Exploiting gender-based biomarkers and drug targets: advancing personalized therapeutic strategies in hepatocellular carcinoma

Case report: a cataract induced by bleomycin in a patient with testicular cancer